Medindia

X

For Kidney Disease Patients, Common Blood Changes Not Independent Predictor of Adverse Outcomes

by Kathy Jones on  August 27, 2010 at 11:36 PM Research News   - G J E 4
Fluctuations in blood composition among kidney disease patients are not an independent predictor of adverse outcomes for European hemodialysis patients.
 For Kidney Disease Patients, Common Blood Changes Not Independent Predictor of Adverse Outcomes
For Kidney Disease Patients, Common Blood Changes Not Independent Predictor of Adverse Outcomes
Advertisement

There are the findings of a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that although hemoglobin variability is common in kidney disease patients, it does not appear to increase their likelihood of dying early.

Advertisement
Research has generated conflicting results on the health impacts that may occur when a person experiences variability in levels of hemoglobin (the component of blood that transports oxygen throughout the body) after taking erythropoiesis stimulating agents (ESAs). These drugs are commonly used to treat anemia in patients with kidney disease. Unfortunately, ESAs can increase the risk of vascular complications and possibly death when used to boost kidney disease patients' hemoglobin levels to what is considered normal (> 13 g/dL) in the general population. In addition, kidney disease patients often have significant fluctuations in hemoglobin levels when using ESAs.

To see if variability of hemoglobin levels over time may have a negative effect on a patient's health, Kai-Uwe Eckardt, MD (University of Erlangen-Nuremberg, Germany) and his colleagues examined data from 5037 European hemodialysis patients treated over two years. "We were able to establish that variability in hemoglobin levels experienced by many hemodialysis patients, per se, does not appear to increase the risk of mortality," said Dr. Eckardt. However, the study did find that patients with consistently low levels of hemoglobin (<11 g/dL) had 2.34-times the risk of dying during the study period; those whose hemoglobin levels fluctuated between normal and <11 g/dL had 1.74-times the risk of dying during the study period.



Source: Eurekalert
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All